Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 15/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 7/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22645537 | 1.00 | IKZF2 (0.51) | IKZF2CRBNESR1IKZF3DDB1 | |
| SCHEMBL20046714 | 0.93 | CRBN (0.54) | IKZF2CRBNESR1IKZF3DDB1 | |
| SCHEMBL22645556 | 0.92 | CRBN (0.58) | IKZF2CRBNESR1IKZF3DDB1 | |
| SCHEMBL22645559 | 0.92 | CRBN (0.58) | IKZF2CRBNESR1IKZF3DDB1 | |
| SCHEMBL20046717 | 0.90 | CRBN (0.54) | IKZF2CRBNESR1IKZF3DDB1 | |
| SCHEMBL29597826 | 0.90 | IKZF2 (0.47) | IKZF2CRBNESR1IKZF3DDB1 | |
| SCHEMBL22661330 | 0.89 | IKZF2 (0.48) | IKZF2CRBNESR1IKZF3DDB1 | |
| SCHEMBL23158456 | 0.88 | IKZF2 (0.67) | IKZF2CRBNESR1IKZF1 | |
| SCHEMBL26609341 | 0.86 | CRBN (0.53) | IKZF2CRBNESR1IKZF3DDB1 | |
| SCHEMBL29597401 | 0.85 | CRBN (0.56) | IKZF2CRBNESR1IKZF3DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135173-A1 | NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4089083-A1 | PIPERIDINE-2,6-DIONE SUBSTITUTED ISOINDOLES IN THE PREPARATION OF SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | Accutar Biotechnology Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-113329999-B | Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degrading activity and uses thereof | 冰洲石生物科技公司 | 2022-07-01 | — | — | CN | disclosed |
| US-11312702-B2 | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3795570-B1 | SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-113329999-A | Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degrading activity and uses thereof | 冰洲石生物科技公司 | 2021-08-31 | — | — | CN | disclosed |
| WO-2021061204-A1 | NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20210087169-A1 | NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-03-25 | — | — | US | disclosed |
| EP-3795570-A1 | SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | Accutar Biotechnology Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10836749-B1 | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087169-A1 | NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, NR5A1, ESRRA | IKZF2 4352/4885CRBN 409/4885ESR1 16/4885 |
| US-20230135173-A1 | NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, NR5A1, ESRRA | IKZF2 4352/4885CRBN 409/4885ESR1 16/4885 |
| US-11312702-B2 | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | AR, NR5A1, ESRRA | IKZF2 4290/4885CRBN 357/4885ESR1 13/4885 |
| US-10836749-B1 | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | AR, NR5A1, ESRRA | IKZF2 4290/4885CRBN 357/4885ESR1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.